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The influence of dosing intervals on the activity of gentamicin and ticarcillin against
Pseudomonas aeruginosa was studied in vivo. Granulocytopenic mice infected with
P. aeruginosa in the thigh muscle were treated with l-hr or 3-hr injections of gentamicin,
ticarcillin, or gentamicin-ticarcillin. Plasma pharmacokinetics of the drugs were corre-
lated with antibacterial activity. Gentamicin injected every 1 hr tended to be less active
than gentamicin injected at longer intervals. In contrast, ticarcillin given every 1 hr was
significantly more efficacious than equivalent total doses injected every 3 hr. The dos-
ing schedule of gentamicin-ticarcillin was again important for ticarcillin but did not ap-
preciably affect the antibacterial activity of gentamicin. Thus, antimicrobial chemo-
therapy of P. aeruginosa infections in the granulocytopenic host might be improved by
administering ticarcillin rather than gentamicin as a constant infusion.
The optimal antibiotic treatment of gram-negative
bacterial infections in granulocytopenic patients
remains an unsolved clinical problem, particularly
for infections due to Pseudomonas aeruginosa, al-
though progress has been made by combining
antipseudomonal drugs and by using doses ap-
proaching toxic levels. Additional progress could
possibly be made by finding optimal dosing
schedules for these drugs. This aspect of anti-
microbial chemotherapy has hardly been investi-
gated. In some recent clinical trials aminoglyco-
side antibiotics were administered as constant
infusions [1-3]. Although it was concluded that
such infusions might be more effective than inter-
mittent dosing, the results supporting this conclu-
sion were not significant. In vitro, no superiority
could be demonstrated for constant infusions vs,
intermittent doses of gentamicin against P. aeru-
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ginosa [4]. An early experimental approach to
the importance of dosing schedules in an experi-
mental model in vivo [5] has never been further
explored nor has it been expanded to the immuno-
compromised host.
In the present study an attempt was made to
elucidate the impact of dosing intervals on the ac-
tivity of gentamicin and ticarcillin against P. aeru-
ginosa in granulocytopenic mice. For each drug
alone and in combination the antibacterial effect
of identical total amounts of drug given by two
different dosing schedules was quantitated and
compared: a 3-hr schedule, which during dosage
intervals allowed plasma drug levels to fall below
the MIC for the target organism, and a l-hr regi-
men, which did not.
Materials and Methods
Organisms. P. aeruginosa strain ATCC 27853
(American Type Culture Collection, Rockville,
Md.) was the main study organism. A previously
well-studied clinical isolate (14974) [4, 6, 7] and
two recent clinical isolates (A 10 and E 29/2), all
from the Institute of Medical Microbiology (Bern,
Switzerland), were included in confirmatory ex-
periments. All organisms studied were susceptible
to gentamicin and ticarcillin by the method of
Bauer et al. [8]. MICs and MBCs for the main
study organism as determined with various meth-
ods and media are shown in table 1.
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Table 1. MICs (J,lg/ml) and MBCs (J,lg/ml) of gentamicin and ticarcillin for Pseudomonas aeruginosa strain ATCC
27853, as determined using various techniques, media, and bacterial inocula.
Inoculum!
Drug Method Medium" "'5 x 105 cfu/mtl rv107 cfu/ml§
Gentamicin Agar dilution MHA 2(-) 2(-)
Macrodilution MHB 0.25 (0.5) 0.5 (1)
SMHB 2 (4) 4 (8)
Ticarcillin Macrodilution MHB 32 (32) 64 (>256)
• MHA = Mueller-Hinton agar; MHB = Mueller-Hinton broth; SMHB ::: MHB supplemented with 50 mg of Ca" and 20 mg
of Mg't/liter. Corresponding media were used to dilute the drug as well as the inoculum.
t MIC (MBC, defined as ~3 - log reduction of cfu by 24 hr).
+By agar dilution method 5 x 103 cfu per spot.
§ By agar dilution method 5 x 105 cfu per spot.
Media. Mueller-Hinton broth and Mueller-
Hinton agar (BBL Microbiology Systems, Cockeys-
ville, Md.) used for preliminary in vitro studies
were supplemented with Ca" and Mg" according
to the procedure of Stratton and Reller [9]. MICs
and MBCs were determined in Mueller-Hinton
broth and supplemented Mueller-Hinton broth
according to standard methods [l0].
Drugs. Gentamicin and ticarcillin used for in
vitro MIC determinations were powders obtained
from Schering Corp. (Kenilworth, N.J.) and
Beecham Laboratories (Bristol, Tenn.), respec-
tively. Drugs used for in vivo studies were com-
mercial products: cyclophosphamide (Mead John-
son Pharmaceuticals, Evansville, Ind.), genta-
micin (Schering), and ticarcillin (Beecham).
Mice. Female ICR mice weighing 26-30 g each
were obtained from Harlan Sprague Dawley
(Madison, Wis.) and Tierzucht der Universitat
Tierspital (Zurich).
Production and confirmation of granulocyto-
penia. Granulocytopenia was produced by two ip
injections of cyclophosphamide, 150 and 100 tJg/g
at four days and one day, respectively, before the
mice were infected with P. aeruginosa. Leuko-
penia was confirmed in six to 10 animals in each
experiment on day 4 or 5 after the first injection
of cyclophosphamide. Blood (20 J.L1) was drawn
from the retroorbital sinus into Unopettes'" capil-
lary pipettes (BBL), and leukocytes were counted
with a Coulter counter (Coulter Electronics, Hia-
leah, Fla.). In addition, blood smears were
checked for the presence of granulocytes in some
but not all experiments.
Drug kinetics. Concentrations of antibiotics
were determined in three to six animals per sam-
pling point. With the animal under slight ether
anesthesia, blood was drawn from the retroorbital
sinus into heparinized micro-hematocrit tubes
(Clay Adams, Parsippany, N.Y.). Plasma drug
levels were determined in a biologic assay [11]
using Bacillus subtilis strain ATCC 6633 (Difco
Laboratories, Detroit) as the indicator organism.
Bacterial inocula and injection ofmice. Broth
cultures of the study organisms were grown to an
OD of 0.3 (measured at 580 nm), washed in ice-
cold 0.9070 NaCI, and adjusted to an OD of 0.3 in
0.9070 NaCl. Of this suspension, 0.1 ml (corre-
sponding to rvl07 cfu) was injected into the thigh
of a slightly ether-anesthetized granulocytopenic
mouse on day 4 of the experiment (that is, four
days after the first injection of cyclophospha-
mide).
Quantitation of bacterial growth and killing.
At various intervals after injection of the bacterial
inoculum, three mice of each group were killed for
study. The infected thigh was removed, immedi-
ately homogenized in 4 ml of iced saline (8.5 g of
NaCl/liter) supplemented with 50 mg of Ca'"/
liter, 20 mg of Mg'"/liter, and 0.1 ml of fJ-Iacta-
mase (Whatman Biochemicals, Maidstone, Kent,
England) with a Polytron'" tissue homogenizer
(Kinematica, Lucerne, Switzerland), and plated in
duplicate for cfu determinations.
Treatment of mice. Granulocytopenic mice
were allotted to treatment groups, being treated
essentially with either a l-hr or a 3-hr regimen.
Experiments were devised such that identical cu-
mulative doses of the study drug(s) resulted by the
time the animals were killed for study. Animals
were injected sc with 0.2 ml of appropriate dilu-
tions of the drugs. Control mice were injected with
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0.9010 NaCI. The range of doses studied was 10
ug/g per 1 hr to 1 mg/g per 3 hr and 0.833 J.tg/g
per 1 hr to 22.5 J.tg/g per 3 hr for ticarcillin and
gentamicin, respectively. In combination experi-
ments, the two study drugs were injected simul-
taneously at two different sites.
Evaluation of results and statistics. The direct
comparison of results (the effect of identical cum-
ulative doses of drug administered by different
schedules) was based on experiments performed
with the same bacterial inoculum on the same day
injected into randomly selected granulocytopenic
mice.
Calculations of the t Y2 values of gentamicin and
ticarcillin were based on the assumption that the
drug had been absorbed from the site of injection
by 15 min after the injection. Analysis of regres-
sion and analysis of covariance [12] were used to
evaluate bacterial growtn curves and dose-response
curves for the two study drugs. Wilcoxon's tank
sum test for paired samples [12] was used for an-
alyzing results compiled from various and re-
peated experiments comparing the effect of differ-
ent dosing schedules.
Results
Granulocytopenia in mice. Mice were severely
granulocytopenic (absolute granulocyte count,
<50/mm3) by day 4 and remained so through day
5 after the first injection of cyclophosphamide.
Virtually no granulocytes were found on smears
made from blood as well as from Pseudomonas-
infected thighs of such mice.
Ticarcillin treatment. The plasma kinetics of
ticarcillin were similar in infected and noninfected
mice. Plasma levels after sc injection of various
doses of ticarcillin are shown in figure 1, left. As-
suming complete absorption of the drug by 15 min
after sc injection of 1 mg/g, the t Y2 of ticarcillin
was 15.6 min.
Figure 2 shows the kinetics of two dosing regi-
mens of ticarcillin as well as the corresponding an-
tipseudomonal effect in the same animals. Gran-
ulocytopenic mice were injected in the thigh mus-
cle with P. aeruginosa strain ATCC 27853. At 2 hr
later, ticarcillin treatment was started with 30 J.tg/g
every 3 hr in one group and with 10 J.tg/g every 1
hr in another group. Peak plasma levels after 30
J.tg/g came close to the MIC for the study organ-
isms (16-32 ug/ml) but remained clearly below the
MBC, as determined with an inoculum of 10'
cfu/ml in vitro (>256 J.tg/ml). Doses every 1 hr of
10 J.tg/g resulted in plasma drug levels that re-
mained below the MIC for the study organisms
throughout the experiment. No significant accum-
ulation of ticarcillin was observed. Neither of the
two dosing regimens was bactericidal. Yet, bacte-
rial growth was suppressed in animals treated
every 1 hr for at least 12 hr. In contrast, doses
every 3 hr of 30 J.tg/g were significantly less active,
allowing for growth of the study organisms
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Figure 1. Plasma kinetics of (left) ticarcillin and (right) gentamicin in mice after single sc injections of various doses.
Each point represents the mean ± SD of duplicate determinations from three to (left) six or (right) four mice. Limit
of detectability = (- - -); Pseudomonas aeruginosa strain NCTC 104941 used as indicator organism = (*).
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Figure 3. Effect of variouscumulative dosesof ticarcil-
lin, injected at 1- or 3-hr intervals, in granulocytopenic
mice infected with Pseudomonas aeruginosa. Data are
geometric mean ± SD values (n = 3) of log cfu (f) -
log cfu (fo), where fo is the time when treatment was
started and t is the time after starting the treatment.
Valuesfor dose-response curvesat 6 hr of treatment (for
l-hr and 3-hrdosing, respectively) werer = -0.914 and
-0.886, intercept = 1.57 and 2.7, and slope = -1.01
and - 1.06; at 12 hr of treatment, r = - 0.897 and
-0.965, intercept = 2.03 and 5.3, and slope = -0.88
and - 1.67. Data from figure 1 = (*).
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sponse curves (x for y = 0). At 6 hr of treatment
the bactericidal threshold doses of the l-hr and the
3-hr schedule were 72 and 724 ug/g per 6 hr, re-
spectively (with 0.95 confidence limits 21 ~ 72
~ 199 and 211 ~ 724 ~ 2,993 J.ig/g per 6 hr for l-hr
and 3-hr dosing schedules, respectively). Corre-
sponding bactericidal threshold doses at 12 hr of
treatment were 51 ~ 207 ~ 703 and 776 ~ 1,473
~ 2,945 ug/g per 12 hr, respectively. Thus, l-hr in-
jections were estimated to be about seven to 10
times more effective than 3-hr injections yielding
identical cumulative doses of ticarcillin. No mode
of dosing was more effective after 12 hr of therapy
than after 6 hr. Moreover, a trend toward bacte-
rial breakthrough growth was noted even in mice
receiving high-dose treatment.
Confirmatory studies included three clinical iso-
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despite the intermittent higher blood levels of
ticarcillin obtained.
Additional experiments in granulocytopenic
mice were performed using doses of up to 1 mg of
ticarcillin/g. Again, the activity of a 1-hr vs. a 3-hr
dosage regimen was studied. The antibacterial ef-
fect of ticarcillin proved (1) to be dose related, (2)
to depend on the dosage interval, and (3) to fade
in prolonged treatment. For both dosing regimens
a significant correlation between the log of dose
and the pharmacologic response was obtained
(figure 3). In addition, a highly significant differ-
ence in antipseudomonal efficacy was demon-
strated between 1-hr and 3-hr dosing schedules of
ticarcillin (P < 0.01 by Wilcoxon's rank sum test).
A bactericidal threshold dose, defined as the mini-
mal cumulative dose of drug above which a reduc-
tion in numbers of living bacteria from infected
thighs was observed, was calculated from dose-re-
Figure 2. Kinetics of sub-MIC levels of ticarcillinand
the corresponding effect on Pseudomonas aeruginosa
strain ATCC 27853 in the same granulocytopenic mice.
Top,growthkinetics of P. aeruginosa in vivo.Each point
represents the geometric mean ± SD number of cfu per
thigh in three mice. The differences among the three
growth curvesare significant (P< 0.01).Bottom, plasma
kinetics after repeated3-hr and l-hr sc injections of ticar-
cillin (30 and 10 ug/g, respectively). Each point stands
for the mean ± SD plasma level in three mice. Limit of
detectability (1 I-tg/ml) = (- - -).
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Figure 4. Effect of various cumulative doses of gen-
tamicin, injected at 1-, 3-, 6-, or 12-hr intervals, in
granulocytopenic mice infected with Pseudomonas
aeruginosa. The MIC of gentamicin for the study
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resulting drug level had fallen below the MIC).
Thereafter, regrowth of the surviving organisms
occurred. This regrowth was relatively slow when
compared with the growth rate of control organ-
isms in saline-treated mice (data not shown). It is
interesting that bacterial killing was observed only
during the first 3 and 6 hr of treatment, even in
those groups of mice that had been injected with
gentamicin every 1 hr or 3 hr. Later on, no signifi-
cant additional killing of the study organism oc-
curred, although drug injections were continued.
The antipseudomonal activity of identical cum-
ulative doses of gentamicin at 3 and 6 hr of treat-
ment (figure 4) was compared. A trend toward
superiority of 3-hr over l-hr injections of gentami-
cin was noted. This trend was corroborated in ad-
ditional experiments using various inocula of
P. aeruginosa strain ATCC 27853 and treatment
with gentamicin at doses of 5, 7.5, and 15 JAg/g per
3 hr (data not shown). A small superiority of 3-hr
lates of P. aeruginosa. Two of these strains
(strains E 29/2 and A 10) were highly virulent in
mice and grew faster than strain ATCC 27853 in
vitro and in vivo. They were susceptible to ticarcil-
lin at an MIC of 32 ug/ml. In contrast, the third
clinical isolate (strain 14974, from a child with
cystic fibrosis) grew markedly slower in vitro and
in granulocytopenic mice and was susceptible to
ticarcillin at an MIC of 2 JAg/m!. In all confirma-
tory experiments using these three strains, l-hr
doses of ticarcillin were significantly more effica-
cious than 3-hr doses. In fact, a 3-hr treatment
regimen of ticarcillin using 90 JAg/g per 3 hr did
not have a bactericidal effect on strain 14974, even
though peak drug levels exceeded the MBC for
this organism by at least 32-fold.
Gentamicin treatment. Plasma levels after
various doses of gentamicin are shown in figure 1,
right. Assuming complete absorption of the drug
by 15 min after sc injection of 90 JAg/g, a tY2 of 19
min was found. This tY2 tended to be even shorter
after injections of lower doses of gentamicin. Ac-
cumulation of the drug was occasionally observed
in extremely sick mice by 12 hr of treatment. It is
interesting that cfu counts per thigh in such mice
did not differ from those in mice in which the drug
had not accumulated.
Granulocytopenic mice infected with P. aerugi-
nosa were comparatively treated with various
doses and dosage schedules of gentamicin. Figure
4 depicts results compiled with P. aeruginosa
strain ATCC 27853. At doses of gentamicin up to
2.5 JAg/g per 1 hr and 7.5 JAg/g per 3 hr, respec-
tively, the efficacy of a l-hr and a 3-hr dosage
schedule was comparable. Both regimens resulted
in bacterial breakthrough growth, even when peak
plasma levels, at least intermittently, exceeded the
MIC for the study organism. Higher doses of gen-
tamicin (90 JAg/g per 12 hr) were comparatively
studied in four different groups of mice injected
every 1 hr, every 3 hr, every 6 hr, or only once per
12-hr period of treatment. A similar partial bac-
tericidal effect was obtained in all four groups of
mice at 12 hr of treatment. By this time, the total
amount of injected drug was equal in the four dos-
age regimens studied (that is, cumulative doses of
ticarcillin were identical). In contrast, the time
course of the bactericidal effect was not the same
in the four regimens. The 6-hr and the 12-hr treat-
ment regimens were most efficacious at 3 hr after
the first injection of gentamicin (by which time the
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Figure 5. Effect of various cumulative doses of ticarcil-
lin (T) plus gentamicin (0) in granulocytopenic mice in-
fected with Pseudomonas aeruginosa. Left: T (75 IAg/g
every 3 hr) + 0 (0.67 ug/g every 1 hr); T (75 ug/g every
3 hr) + 0 (2 IAg/g every 3 hr); T (25 IAg/g every 1 hr)
+ 0 (0.67 IAg/g every 1 hr); or T (25 IAg/g every 1 hr)
+ 0 (2 IAg/g every 3 hr). Right: Three and 3.75 times
higher doses of T and 0, respectively.
for a sustained bactericidal effect of ticarcillin in
particular. In confirmatory experiments using two
clinical isolates (P. aeruginosa 14974and E 29/2),
the dosing schedule again turned out to be of par-
ticular importance for ticarcillin, whereas its im-
pact on the activity of gentamicin was not statis-
tically significant in ticarcillin-gentamicin com-
binations.
Using an experimental thigh infection model in
granulocytopenic mice, we demonstrated the im-
pact of doses and dosing schedules on the time
course of the pharmacologic response to two anti-
pseudomonal drugs differing basically in their
mechanism of action.
In comparison to humans, unusually high doses
of ticarcillin and gentamicin were needed to obtain
-;;-2
,§
~
--3
1
~+1
01
E 0
over 1-hr treatment schedules was observed, which
proved to be reproducible and consistent when
results were compiled from seven experiments (P
< 0.01 by Wilcoxon's rank sum test for paired
samples). However, as can be seen from figure 4,
this superiority was limited to sampling points at
3 and 6 hr of treatment. By 12 hr, when the
phenomenon of breakthrough growth became
substantial, no such difference could be demon-
strated.
All essential results obtained with P. aeruginosa
strain ATCC 27853 were confirmed in similar ex-
periments using clinical isolates 14974and E 29/2
as the target organism.
Combined treatment with ticarcillin and genta-
micin. In preliminary experiments, in vivo syner-
gy had been demonstrated for the two study drugs
in combination. Therefore, relatively low and in-
termediate doses of the drugs were studied in com-
bination experiments. Dosing regimens using l-
and 3-hr intervals were compared.
The four possible combinations were simulta-
neously investigated. (1) Granulocytopenic mice
were treated by the schedule by which each drug
had been demonstrated to be least active when
given alone, that is, ticarcillin every 3 hr and gen-
tamicin every 1 hr, (2) a second group got both
drugs every 3 hr, and (3) a third group got both
drugs every 1 hr. (4) A fourth group was treated
with ticarcillin every 1 hr plus gentamicin every 3
hr, that is, the schedule by which each drug, when
given alone, had proved to be most potent.
The results (figure 5) were as expected. Signifi-
cantly most effective was the combination of l-hr
injections of ticarcillin with 3-hr injections of gen-
tamicin. Combining 3-hr doses of ticarcillin with
1-hr doses of gentamicin proved to be the least ac-
tive regimen studied. An analysis of all combina-
tion experiments demonstrated the significant (P
< 0.01) superiority of 1-hr vs. 3-hr regimens of
ticarcillin. This superiority did not depend on
whether the concomitantly administered gentami-
cin was injected every 1 hr or every 3 hr. In con-
trast, gentamicin in combination with any ticarcil-
lin schedule studied tended to be more active in
3-hr than in 1-hr regimens (P <0.05 and P> 0.05
for the lower and higher doses of gentamicin
studied, respectively). Breakthrough growth was
common predominantly when low doses and less
favorable schedules were used. High-dose treat-
ment and optimal dosing intervals were essential
916
an antibacterial effect in mice. This finding could
be explained, at least in part, by the very short t Y2
of these drugs in mice. Therefore, our studies in-
cluded dosing such that peak plasma levels and/or
total area-under-the-concentration-vs.-time curves
rather than injected amounts of drug were com-
parable to those seen in patients receiving maximal
doses of gentamicin or ticarcillin. Interesting dif-
ferences in efficacy were found between such dos-
ing of the two drugs. Gentamicin (2.5 IJg/g every
1 hr or 7.5 IJg/g every 3 hr) had only a small and
transient effect, whereupon breakthrough growth
of the study organisms occurred. This phenome-
non has been the subject of previous investigations
using the same study organisms [6, 7]. Ticarcillin,
on the other hand, even at relatively low doses
«75 IJg/g every 1 hr) was significantly more ef-
ficacious, with the condition that the interval be-
tween drug injections was 1 but not 3 hr. When
properly spaced, even sub-MIC peak levels of
ticarcillin were quite effective, although only bac-
teriostatic. Thus, in contrast to gentamicin, the
effect of ticarcillin was mainly due to the constant
presence of the drug, rather than to very high peak
levels. These differences in activity between ticar-
cillin and gentamicin cannot easily be explained by
the difference in t Y2 of the two study drugs. Other
factors are likely to be involved.
The presence or absence of a postantibiotic ef-
fect could well be of importance in regard to the
results of our present study. In vitro exposure of
P. aeruginosa to gentamicin has been shown to be
followed by a period of persistent suppression of
bacterial regrowth lasting up to 2 hr after removal
of the drug [4, 13]. In contrast, no postantibiotic
effect could be demonstrated with ticarcillin [13].
Thus, in vitro as well as in vivo, P. aeruginosa
seems to recover immediately as soon as the ticar-
cillin level has fallen to subactive concentrations,
whereas the postantibiotic effect of gentamicin
would help to cover the dosing interval of this
drug. Yet, this interpretation would not explain
our results obtained in experiments combining the
two study drugs. In those experiments l-hr injec-
tions of ticarcillin were significantly more active
than 3-hr doses, although theoretically the postan-
tibiotic effect of gentamicin should have covered
the interval between the 3-hr injections of ticarcil-
lin. This finding clearly demonstrates that addi-
tional important factors for optimal administra-
tion of antibiotics have to be taken into account.
Gerber et al.
In this regard, the time lag between drug exposure
and onset of bacterial killing might be of para-
mount importance. After exposure of P. aerugi-
nosa to gentamicin, this time lag is short and de-
pendent on drug concentration in vitro as well as
in vivo [4, 7]. In contrast, in the case of penicillins
this time lag before the onset of bacterial killing
seems to be considerably longer [14, 15] (A.V.G.
and C.F., unpublished observation). Thus, very
short concentration peaks (due to very rapid elim-
ination of the drug) could minimize the in vivo
activity of ticarcillin.
It is clear that much additional experimental
work is needed, both in vitro and in vivo, to un-
derstand how the shape of the concentration-vs.-
time curve of an antibiotic affects its antimicrobial
activity. Moreover, the answer to this question is
certainly dependent not only on the antibiotic, its
pharmacokinetics, and its mechanism of action,
but equally so on the site of infection and the tar-
get organism. Our investigations are no more than
a first tentative approach to a complex problem.
Nevertheless, speculatively extrapolating the re-
sults of our findings to the clinical situation, one
would postulate that, at least in the presence of
leukopenia, ticarcillin rather than an aminoglyco-
side should be administered as a continuous infu-
sion. It is ironic that this postulate is the exact op-
posite of what several authors of clinical studies
have advocated in recent years [1-3].
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